Dermatology

The Pharmacy Times® Dermatology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of skin disorders, including psoriasis, atopic dermatitis, eczema, and acne.

FDA Approves Dupilumab for Adult Patients With Prurigo Nodularis

September 29, 2022

Article

Dupilumab is the first and only medicine approved specifically for the treatment of prurigo nodularis in the United States.

Tremfya Shows Higher Skin Clearance Rates With Earlier Treatment for Plaque Psoriasis

September 21, 2022

Article

Janssen’s GUIDE data demonstrate that patients treated with guselkumab less than 2 years after disease onset vs later are more likely to achieve “super-responder” at week 20 through 28.

Long-Term Data Show Efficacy of Deucravacitinib Maintained Up to 2 Years in Moderate-to-Severe Plaque Psoriasis

September 15, 2022

Article

Deucravacitinib is a selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, which is a member of the Janus kinase (JAK) family.

FDA Accepts New Drug Application for Ritlecitinib for Patients 12 Years of Age and Older With Alopecia Areata

September 15, 2022

Article

Alopecia areata is an autoimmune disease with an underlying immuno-inflammatory pathogenesis.

Lebrikuzumab Found to Maintain Durable Skin Clearance When Dosed Every 4 Weeks in Atopic Dermatitis

September 14, 2022

Article

ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.

New Data for Apremilast Show Significant Improvement in Measures of Moderate to Severe Plaque Psoriasis in Children

September 13, 2022

Article

It is currently indicated for the treatment of adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with Behçet's Disease.

FDA Approves Spevigo for Treatment of Generalized Pustular Psoriasis Flares in Adults

September 12, 2022

Article

Boehringer Ingelheim’s monoclonal antibody inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for this indication.

FDA Approves Deucravacitinib for Adults With Moderate-to-Severe Plaque Psoriasis

September 12, 2022

Article

Deucravacitinib (Sotyktu) may become the new standard of care oral therapy for moderate-to-severe plaque psoriasis, according to investigators.

Daily OTC Pearl: On-the-Spot

August 30, 2022

Article

Neutrogena On-the-Spot with benzoyl peroxide helps reduce treat acne breakouts.

Daily OTC Pearl: Triple Paste Ointment

August 23, 2022

Article

Triple Paste Ointment is used to treat rashes, including diaper rash.